Recursion(US:RXRX) ZACKS·2025-07-30 22:45Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.81, reflecting a -2.35% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.13% [1] - The stock has increased by 15.98% over the past month, contrasting with the Medical sector's loss of 0.96% and the S&P 500's gain of 3.39% [1] Earnings Projections - The upcoming earnings report for Recursion Pharmaceuticals is scheduled for August 5, 2025, with projected EPS of -$0.35, indicating a 12.50% increase from the same quarter last year [2] - The consensus estimate for revenue is $14.38 million, which represents a 0.3% decline from the equivalent quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates forecast full-year earnings of -$1.35 per share and revenue of $68.39 million, reflecting year-over-year changes of +20.12% and +16.23%, respectively [3] Analyst Estimates - Recent modifications to analyst estimates for Recursion Pharmaceuticals are crucial as they reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - Adjustments in estimates are linked to stock price performance, and the Zacks Rank system has been established to leverage these changes [5] Zacks Rank - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [6] - Currently, Recursion Pharmaceuticals holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having decreased by 0.75% over the past month [6] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]